ReviewJournal of diabetes and metabolic disorders2025
Psychological and behavioral effects of GLP-1 and GIP agonists in weight loss: a comprehensive review.
Review in Journal of diabetes and metabolic disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Association of a near-MC4R gene variant (rs17782313) with hyperphagia among patients with severe obesity.Journal of diabetes and metabolic disorders · 2026Article
- The pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medications.Journal of diabetes and metabolic disorders · 2026Review
- Costs of Comorbidities and Complications Associated with Type 2 Diabetes: A Retrospective, Cohort Study.Advances in therapy · 2026Article
- Behavior change support in the new era of obesity care.BMC medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationale: Obesity remains a major global health challenge, severely affecting metabolic and cardiovascular health. Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptor agonists mark a significant breakthrough in diabetes and obesity management, significantly aiding in weight loss and glycemic control. Tirzepatide, a dual agonist for GLP-1 and GIP receptors, effectively promotes weight loss and improves metabolic parameters by influencing insulin secretion, appetite regulation, and gastric emptying. Objectives: This review highlights the dual metabolic and psychological impacts of GLP-1 and GIP agonists in diabetes and obesity management, emphasizing the need for a holistic, patient-centered approach to optimize treatment outcomes. Results: While GLP-1 and GIP agonists demonstrate significant metabolic benefits, their long-term use is often limited by gastrointestinal side effects and psychological impacts. These medications, while regulating appetite and food reward pathways, can also lead to mood disturbances and altered eating behaviors, potentially affecting patient adherence. Conclusions: A comprehensive strategy for obesity management using GLP-1 and GIP agonists must consider both metabolic and psychological factors. Future research should focus on elucidating the complex mechanisms underlying their psychological effects and integrating mental health considerations into therapeutic strategies. Personalized diet and exercise interventions, alongside pharmacological treatments, are crucial for enhancing both metabolic and psychological outcomes, ensuring a more sustainable and effective approach to managing obesity. Graphical Abstract:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.